- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Real-World Implications of the IMpower133 Trial in ES-SCLC
June 28, 2022
Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.
Gilteritinib and Prior Midostaurin/Sorafenib Aids Clinical Response in Patients with FLT3-Mutated AML
June 27, 2022
Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.
Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer
June 27, 2022
During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.
Using Digital Health to Promote Equity in Community Oncology Practices
June 27, 2022
Debra A. Patt, MD, PhD, MBA, discusses a study of digital health systems used at Texas Oncology locations and how it helps with remote communication between patients with cancer and clinicians.
Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC
June 27, 2022
In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.
Novel Liquid Biopsy Performed Favorably Over Needle-Based Biopsies in HER2+ Breast Cancer
June 27, 2022
In patients with HER2-positive breast cancer, an investigational liquid biopsy was more favorable compared with needle biopsies, a study shows.
Case 1: A 59-Year-Old Man With Nonmetastatic CRPC
June 27, 2022
Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.
RCC With Sarcomatoid Features May Benefit From Immunotherapy
June 27, 2022
Matthew T. Campbell, MD, discusses the results of a retrospective analysis of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation.
Overview of Prostate Cancer and Treatment Modalities
June 27, 2022
Experts provide comprehensive insight on prostate cancer, covering its prevalence, subtypes, and the systemic treatment armamentarium.
Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host Disease
June 27, 2022
During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.
Roundtable Discussion: Voorhees Discusses Managing Treatment in Multiple Myeloma
June 26, 2022
During a Targeted Oncology case-based roundtable event, Peter Voorhees, MD, discussed therapy options and transplant eligibility for patients with multiple myeloma.